These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38702786)

  • 1. Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model.
    Archer KJ; Fu H; Mrózek K; Nicolet D; Mims AS; Uy GL; Stock W; Byrd JC; Hiddemann W; Braess J; Spiekermann K; Metzeler KH; Herold T; Eisfeld AK
    J Hematol Oncol; 2024 May; 17(1):28. PubMed ID: 38702786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined molecular and clinical prognostic index for relapse and survival in cytogenetically normal acute myeloid leukemia.
    Pastore F; Dufour A; Benthaus T; Metzeler KH; Maharry KS; Schneider S; Ksienzyk B; Mellert G; Zellmeier E; Kakadia PM; Unterhalt M; Feuring-Buske M; Buske C; Braess J; Sauerland MC; Heinecke A; Krug U; Berdel WE; Buechner T; Woermann B; Hiddemann W; Bohlander SK; Marcucci G; Spiekermann K; Bloomfield CD; Hoster E
    J Clin Oncol; 2014 May; 32(15):1586-94. PubMed ID: 24711548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
    J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel molecular markers for prognosis estimation of acute myeloid leukemia: over-expression of PDCD7, FIS1 and Ang2 may indicate poor prognosis in pretreatment patients with acute myeloid leukemia.
    Tian Y; Huang Z; Wang Z; Yin C; Zhou L; Zhang L; Huang K; Zhou H; Jiang X; Li J; Liao L; Yang M; Meng F
    PLoS One; 2014; 9(1):e84150. PubMed ID: 24416201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of Risk Factors for Relapse in Childhood Leukemia Using Penalized Semi-parametric Mixture Cure Competing Risks Model.
    Mehrbakhsh Z; Tapak L; Behnampour N; Roshanaei G
    J Res Health Sci; 2024 Jun; 24(2):e00615. PubMed ID: 39072551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome abnormalities at onset of complete remission are associated with worse outcome in patients with acute myeloid leukemia and an abnormal karyotype at diagnosis: CALGB 8461 (Alliance).
    Niederwieser C; Nicolet D; Carroll AJ; Kolitz JE; Powell BL; Kohlschmidt J; Stone RM; Byrd JC; Mrózek K; Bloomfield CD
    Haematologica; 2016 Dec; 101(12):1516-1523. PubMed ID: 27470602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
    Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
    J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group.
    Haferlach T; Kern W; Schoch C; Schnittger S; Sauerland MC; Heinecke A; Büchner T; Hiddemann W;
    Haematologica; 2004 Apr; 89(4):408-18. PubMed ID: 15075074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
    Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
    J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG).
    Gaidzik VI; Schlenk RF; Paschka P; Stölzle A; Späth D; Kuendgen A; von Lilienfeld-Toal M; Brugger W; Derigs HG; Kremers S; Greil R; Raghavachar A; Ringhoffer M; Salih HR; Wattad M; Kirchen HG; Runde V; Heil G; Petzer AL; Girschikofsky M; Heuser M; Kayser S; Goehring G; Teleanu MV; Schlegelberger B; Ganser A; Krauter J; Bullinger L; Döhner H; Döhner K
    Blood; 2013 Jun; 121(23):4769-77. PubMed ID: 23632886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.
    Becker H; Marcucci G; Maharry K; Radmacher MD; Mrózek K; Margeson D; Whitman SP; Wu YZ; Schwind S; Paschka P; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 Feb; 28(4):596-604. PubMed ID: 20026798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
    Marcucci G; Maharry K; Wu YZ; Radmacher MD; Mrózek K; Margeson D; Holland KB; Whitman SP; Becker H; Schwind S; Metzeler KH; Powell BL; Carter TH; Kolitz JE; Wetzler M; Carroll AJ; Baer MR; Caligiuri MA; Larson RA; Bloomfield CD
    J Clin Oncol; 2010 May; 28(14):2348-55. PubMed ID: 20368543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Marcucci G; Maharry K; Whitman SP; Vukosavljevic T; Paschka P; Langer C; Mrózek K; Baldus CD; Carroll AJ; Powell BL; Kolitz JE; Larson RA; Bloomfield CD;
    J Clin Oncol; 2007 Aug; 25(22):3337-43. PubMed ID: 17577018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent DNMT3A mutation burden in DNMT3A mutated adult cytogenetically normal acute myeloid leukemia patients in long-term remission.
    Sun Y; Shen H; Xu T; Yang Z; Qiu H; Sun A; Chen S; Wu D; Xu Y
    Leuk Res; 2016 Oct; 49():102-7. PubMed ID: 27626217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Precision oncology in AML: validation of the prognostic value of the knowledge bank approach and suggestions for improvement.
    Bill M; Mrózek K; Giacopelli B; Kohlschmidt J; Nicolet D; Papaioannou D; Eisfeld AK; Kolitz JE; Powell BL; Carroll AJ; Stone RM; Garzon R; Byrd JC; Bloomfield CD; Oakes CC
    J Hematol Oncol; 2021 Jul; 14(1):107. PubMed ID: 34229733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrative prognostic risk score in acute myeloid leukemia with normal karyotype.
    Damm F; Heuser M; Morgan M; Wagner K; Görlich K; Grosshennig A; Hamwi I; Thol F; Surdziel E; Fiedler W; Lübbert M; Kanz L; Reuter C; Heil G; Delwel R; Löwenberg B; Valk PJ; Krauter J; Ganser A
    Blood; 2011 Apr; 117(17):4561-8. PubMed ID: 21372155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of RASGEF1A RNA expression and DNA methylation in cytogenetically normal acute myeloid leukemia.
    He X; Zhang W; Fu W; Liu X; Yang P; Wang J; Zhu M; Li S; Zhang W; Zhang X; Dong G; Yan C; Zhao Y; Zeng Z; Jing H
    Cancer Biomark; 2023; 36(2):103-116. PubMed ID: 36404533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.
    Walker CJ; Mrózek K; Ozer HG; Nicolet D; Kohlschmidt J; Papaioannou D; Genutis LK; Bill M; Powell BL; Uy GL; Kolitz JE; Carroll AJ; Stone RM; Garzon R; Byrd JC; Eisfeld AK; de la Chapelle A; Bloomfield CD
    Blood Adv; 2021 Mar; 5(5):1474-1482. PubMed ID: 33683341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
    Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
    Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes.
    Greif PA; Konstandin NP; Metzeler KH; Herold T; Pasalic Z; Ksienzyk B; Dufour A; Schneider F; Schneider S; Kakadia PM; Braess J; Sauerland MC; Berdel WE; Büchner T; Woermann BJ; Hiddemann W; Spiekermann K; Bohlander SK
    Haematologica; 2012 Dec; 97(12):1909-15. PubMed ID: 22689681
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.